

Supplementary Data

SUPPLEMENTARY TABLE S1. DEMOGRAPHIC, CLINICAL, AND BIOCHEMICAL CHARACTERISTICS OF THE PATIENTS ACCORDING TO THE STATUS OF ANTI-THYROID PEROXIDASE ANTIBODIES AT THE TIME OF COMMENCEMENT OF THYROID HORMONE REPLACEMENT THERAPY

	Total (n=113)	Hashimoto's SCH (n=45)	Non-Hashimoto's SCH (n=68)	p-Value
Age (years)	63.2±12.7	59.7±12.3	60.5±12.9	0.74
Men	36 (31.9%)	17 (37.8%)	19 (27.9%)	0.27
DM	44 (38.9%)	20 (44.4%)	24 (35.3%)	0.33
Hypertension	69 (61.1%)	30 (66.7%)	39 (57.4%)	0.32
CVD	17 (15.0%)	7 (15.6%)	10 (14.7%)	0.92
Primary disease				
Diabetic nephropathy	44 (38.9%)	20 (44.4%)	24 (35.3%)	0.33
Hypertensive nephrosclerosis	42 (37.2%)	18 (40.0%)	24 (35.3%)	0.61
Chronic GN	17 (15.1%)	5 (11.1%)	12 (17.6%)	0.34
Tubulointerstitial nephritis	6 (5.3%)	2 (4.4%)	4 (6.0%)	0.73
Others	4 (3.5%)	0 (0%)	4 (5.9%)	0.10
Systolic blood pressure (mmHg)	148.9±17.8	146.8±14.6	150.2±19.7	0.49
Diastolic blood pressure (mmHg)	86.5±11.0	85.9±11.2	86.9±11.0	0.74
Mean arterial pressure (mmHg)	107.3±11.7	106.2±10.7	108.0±12.5	0.58
Thyroid function test				
T3 (ng/mL)	1.08±0.29	1.08±0.27	1.08±0.31	0.89
fT4 (ng/dL)	1.09±0.22	1.10±0.25	1.10±0.20	0.99
TSH (μIU/mL)	8.86±5.71	9.95±7.48	8.14±4.07	0.14
Serum creatinine (mg/dL)	1.28±0.50	1.29±0.51	1.27±0.50	0.85
eGFR ([mL/min]/1.73 m ²)	59.5±16.3	58.6±16.0	60.1±16.6	0.64
Serum albumin (g/dL)	4.03±0.89	4.10±0.76	3.99±0.98	0.52
Serum calcium (mg/dL)	9.26±0.65	9.35±0.73	9.20±0.59	0.24
Serum phosphate (mg/dL)	3.84±0.59	3.82±0.62	3.85±0.57	0.78
Serum cholesterol (mg/dL)	171.2±35.5	170.4±32.7	171.8±37.5	0.83
Serum triglyceride (mg/dL)	156.4±111.8	136.3±72.0	169.0±129.9	0.20
Medication use				
RAS blockers	78 (69.0%)	31 (68.9%)	47 (69.1%)	0.98
Calcium channel blockers	37 (32.7%)	14 (31.1%)	23 (33.8%)	0.76
β-blockers	30 (26.5%)	10 (22.2%)	20 (29.4%)	0.40
Diuretics	43 (38.1%)	18 (40.0%)	25 (36.8%)	0.73
Other anti-hypertensive drugs	5 (4.4%)	0 (0.0%)	5 (7.4%)	0.06
Statins	36 (31.9%)	14 (31.1%)	22 (32.4%)	0.89

Values are expressed as mean±standard deviation or number (percentage).

DM, diabetes mellitus; eGFR, estimated glomerular filtration rate (by MDRD-4 equation); GN, glomerulonephritis; RAS, renin-angiotensin system; SCH, subclinical hypothyroidism.